Biogen proposes to buy remaining stake in Sage in $442 million deal
Jan 10 (Reuters) - Drugmaker Biogen BIIB.O will buy all outstanding shares of Sage Therapeutics SAGE.O that it does not already own for $7.22 apiece, a filing showed on Friday, sending the latter's stock up 34% in extended trade.
As per the filing, Biogen has a 10.2% stake in Sage Therapeutics. The offer price, representing a 30% premium to the stock's close on Friday, values Sage's equity at $441.7 million, according to Reuters calculations.
Biogen has been navigating a slow pick-up in sales for its Alzheimer's drug Leqembi in the United States after concerns over cost, efficacy and side effects.
Sage, whose shares fell 74.9% last year, abandoned the development of its drug dalzanemdor after multiple trial failures. The company said in November that it will focus on its postpartum depression drug, Zurzuvae, which it developed in partnership with Biogen.
In July, Sage also scrapped the development of another neurological disorder drug it was developing with Biogen.
(Reporting by Puyaan Singh in Bengaluru; Editing by Alan Barona)
((Puyaan.Singh@thomsonreuters.com))
Related Articles
[U.S. IPO] Valuation Doubles Figma’s Pre-IPO Level — Canva’s Latest Funding Hints at Public Market Debut
TradingKey - Following the strong market reception of design collaboration platform Figma’s IPO, which has reignited momentum for software company listings, another online design platform, Canva, appears to be preparing for a potential public offering.
Two Key Things to Watch in Walmart’s Q2 Earnings: Tariff Pressure and E-Commerce Momentum
TradingKey - U.S. retailer Walmart (WMT) will release its Q2 2026 fiscal earnings before the market opens on August 21. As a key barometer of the U.S. economy and consumer health, Walmart’s results will reveal how tariffs are impacting consumer behavior and corporate profits. Another focus is
U.S. Stock Market Risk Assessment: Learning from History, Mid-Term Outlook Remains Secure
We argue that the Federal Reserve’s monetary policy is the most critical factor influencing the stock market.
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed Chair
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...
